Pioglitazone and metformin fixed-dose combination in type 2 diabetes mellitus: An evidence-based review of its place in therapy

Core Evidence

Volumn 2, Issue 3, 2008, Pages 189-198

  Derosa, Giuseppe ^a   Salvadeo, Sibilla Anna Teresa ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

Cardiovascular risk factors; Diabetes; Metformin; Outcomes; Pioglitazone

Indexed keywords

GLIBENCLAMIDE; GLICLAZIDE; GLICLAZIDE PLUS METFORMIN; GLICLAZIDE PLUS PIOGLITAZONE; GLIMEPIRIDE; GLIMEPIRIDE PLUS PIOGLITAZONE; GLITAZONE DERIVATIVE; METFORMIN; METFORMIN PLUS PIOGLITAZONE; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ADD ON THERAPY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG FATALITY; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; EVIDENCE BASED PRACTICE; FLUID RETENTION; GASTROINTESTINAL SYMPTOM; HEART FAILURE; HUMAN; HYPERTENSION; HYPOGLYCEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; LACTIC ACIDOSIS; LIPID BLOOD LEVEL; LIPID METABOLISM; MONOTHERAPY; MORTALITY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PERIPHERAL EDEMA; REVIEW; RISK REDUCTION; SIDE EFFECT; WEIGHT GAIN;

EID: 65849142786     PISSN: 15551741     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (66)

1. ADA (American Diabetes Association). Standards of medical care in diabetes - 2007. Diabetes Care. 2007;30(Suppl. 1):S4-S41.
2. Ahmann AJ, Riddle MC. Current oral agents for type 2 diabetes. Many options but which to choose when? Postgrad Med. 2002;111:32-46
3. Anon. Actoplus prescribing information. Deerfield, IL: Takeda Pharmaceuticals America, Inc.; 2007. Available at: http://www.actos.com/actos/prescribinginfo.aspx (accessed August 2007).
4. Betteridge DJ, Verges B. Long-term effects on lipids and lipoproteins of pioglitazone versus gliclazide addition to metformin and pioglitazone versus metformin addition to sulphonylurea in the treatment of type 2 diabetes. Diabetologia. 2005;48:2477-2481.
5. Bays HE, Bazata DD, Clark NG, et al. Prevalence of self-reported diagnosis of diabetes mellitus and associated risk factors in a national survey in the US population: SHIELD (Study to Help Improve Early evaluation and management of risk factors Leading to Diabetes). BMC Public Health. 2007;7:277-303.
6. Bolen S, Feldman L, Vassy J, et al. Systematic review: Comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med. 2007;147:386-399.
7. Ceriello A, Johns D, Widel M, et al. Comparison of the effect of pioglitazone with metformin or sulphonylurea (monotherapy and combination therapy) on post-load glycemia and composite insulin sensitivity index during an oral glucose tolerance test in patients with type 2 diabetes. Diabetes Care. 2005;28:266-272.
8. Charbonell BH, Schernthaner G, Brunetti P, et al. Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes. Diabetologia. 2005;48:1093-1104.
9. Czoski-Murray C, Warren E, Chilcott J, et al. Clinical effectiveness and cost-effectiveness of pioglitazone and rosiglitazone in the treatment of type 2 diabetes: A systematic review and economic evaluation. Health Technol Assess. 2004;8:iIi,ix-x, 1-91.
10. Deeks ED, Scott LJ. Pioglitazone/metformin. Drugs. 2006;66:1863-1877.
11. Derosa G, Cicero AF, Gaddi A, et al. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: A twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial. Clin Ther. 2004;26:744-754.
12. Derosa G, D'Angelo A, Ragonesi PD, et al. Effects of rosiglitazone and pioglitazone combined with metformin on the prothrombotic state of patients with type 2 diabetes mellitus and metabolic syndrome. J Int Med Res. 2006a;34:545-555.
13. Derosa G, D'Angelo A, Ragonesi PD, et al. Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome. J Clin Pharm Ther. 2006b;31:375-383.
14. Derosa G, Cicero AFG, D'Angelo A, et al. Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: A multicenter, randomized, double-blind, controlled clinical trial. Clin Ther. 2006c;28:679-688. (erratum: Clin Ther. 2006;28:1483.)
15. Derosa G, D'Angelo A, Ragonesi PD, et al. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with metformin. Int Med J. 2007a;37:79-86.
16. Derosa G, Fogari E, Cicero AF, et al. Blood pressure control and inflammatory markers in type 2 diabetic patients treated with pioglitazone or rosiglitazone and metformin. Hypertens Res. 2007b;30:387-394.
17. Després JP. Potential contribution of metformin in the management of cardiovascular disease risk in patients with abdominal obesity, the metabolic syndrome and type 2 diabetes. Diabetes Metab. 2003;29:6S53-6S61.
18. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366:1279-1286.
19. Einhorn D, Rendell M, Rosenzweig J, et al. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group. Clin Ther. 2000;22:1395-1409.
20. Erdmann E. Microalbuminuria as a marker of cardiovascular risk in patients with type 2 diabetes. Int J Cardiol. 2006;107:147-153
21. Gilmer TP, Roze S, Valentine WJ, et al. Cost-effectiveness of diabetes case management for low-income populations. Health Serv Res. 2007;42:1943-1959.
22. Goldberg RB, Kendall DM, Deeg MA, et al. GLAI Study Investigators. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidaemia. Diabetes Care. 2005;28:1547-1554.
23. Granberry MC, Fonseca VA. Cardiovascular risk factors associated with insulin resistance: Effects of oral antidiabetic agents. Am J Cardiovasc Drugs. 2005;5:201-209.
24. Haffner SM. Abdominal adiposity and cardiometabolic risk: Do we have all the answers?. Am J Med. 2007;120(Suppl. 1):s10-s16.
25. Hanefeld N, Brunetti P, Schernthaner GH, et al. One-year glycemic control with a sulphonylurea plus piolgitazone versus a sulphonylurea plus metformin in patients with type 2 diabetes. Diabetes Care. 2004;27:141-147.
26. Herrmann W, Knapp JP. Hyperhomocysteinemia: A new risk factor for degenerative disease. Clin Lab. 2002;48:471-481.
27. IDF (International Diabetes Federation). Diabetes Atlas. 3rd ed. Brussels: International Diabetes Federation; 2006. Available at http://www.eatlas.idf.org (accessed December 5, 2007).
28. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and the risk of cardiovascular events in patients with type 2 diabetes mellitus. A meta-analysis of randomized trials. JAMA. 2007;298:1180-1188.
29. Jain R, Chawrai S. Advancements in the anti-diabetes chemotherapeutic based on amino acids, peptids and peptidomimetics. Mini Rev Med Chem. 2005;5:469-477.
30. Karim A, Slater M, Bradford D, Schwartz L, Laurent A. Oral antidiabetic drugs: Effect of food on absorption of pioglitazone and metformin from a fixed-dose combination tablet. J Clin Pharmacol. 2007a;47:48-55
31. Karim A, Slater M, Bradford D, et al. Oral antidiabetic drugs: bioavailability assessment of fixed-dose combination tablets of pioglitazone and metformin. Effect on body weight, gender and race on systemic exposures of each drug. J Clin Pharmacol. 2007b;47:37-47.
32. Khan MA, St Peter JV, Xue JL. A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone. Diabetes Care. 2002;25:708-711.
33. Khan M, Xu Y, Edwards G, et al. Effects of pioglitazone on the components of diabetic dyslipidemia: Results of double-blind multicenter randomised studies. Int J Clin Pract. 2004;58:907-912.
34. Krentz AJ, Bailey CJ. Oral antidiabetic agents. Drugs. 2005;65:385-411.
35. Kyvik KO, Green A, Beck-Nielsen H. Concordance rates of insulin dependent diabetes mellitus: A population race study of young Danish twins. BMJ. 1995;311:913-917.
36. Lawrence JM, Reid J, Taylor GJ, et al. Favorable effects of pioglitazone and metformin compared with gliclazide on lipoprotein subfractions in overweight patients with early type 2 diabetes. Diabetes Care. 2004;27:41-46.
37. Maca TH, Ahmadi R, Dergfler K, et al. Influence of lipoprotein (a) on restenosis after femoro-popliteal percutaneous transluminal angioplasty in type 2 diabetic patients. Diab Med. 2002;19:300-306.
38. Mann JI. Diet and risk of coronary heart disease and type 2 diabetes. Lancet. 2002;360:783-789.
39. Matthews DR, Charbonnel BH, Hanefeld M, et al. Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: A randomized, comparative study. Diabetes Metab Res Rev. 2005;21:167-174.
40. Meriden T. Progress with thiazolidinediones in the management of type 2 diabetes mellitus. Clin Ther. 2004;26:177-190.
41. Mirkolf H, Luebben G, Pfuetzner A, et al. Pioglitazone vs glibenclamide: significant differences in glycemic control and treatment failure rates in patients with type 2 diabetes mellitus. Presented at: 66th Scientific Sessions of the American Diabetes Association; June 9-13, 2006; Washington, DC. Abstract n 604 p.
42. MRC/BHF (Medical Research Council/British Heart Foundation). Heart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: Early safety and efficacy experience. Eur Heart J. 1999;20:725-741.
43. National Service Framework for Diabetes. Standards 2001. Available at: www.doh.gov.uk/nsf/diabetes/ (accessed August 2007).
44. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2006;29:1963-1972.
45. Negro R, Dazzi D, Hassan H, et al. Pioglitazone reduces blood pressure in non-dipping diabetic patients. Minerva Endocrinol. 2004;29:11-17.
46. Negro R, Mangieri T, Dazzi D, et al. Rosiglitazone effect on blood pressure and metabolic parameters in nondipper diabetic patients. Diabetes Res Clin Pract. 2005;70:20-25.
47. Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention and congestive heart failure. A consensus statement from the American Heart association and American Diabetes Association. Diabetes Care. 2004;27:256-263.
48. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356:2457-2471.
49. Oerter E, Lippmann-Grob, Luebben G. Pioglitazone vs glibenclamide: Focus on metabolic control and health economic impact. Presented at: 66th Scientific Sessions of the American Diabetes Association; June 9-13, 2006; Washington, DC. Abstract 539-P.
50. Perez A, Khan M, Johnson T, et al. Pioglitazone plus a sulphonylurea or metformin is associated with increased lipoprotein particle size in patients with type 2 diabetes. Diab Vasc Dis Res. 2004;1:44-50.
51. Perez A, Spanheimer R, Kupfer S, et al. Cardiovascular safety profile of pioglitazone vs glyburide: Results from a 3-year randomized, double blind trial. Presented at: 66th Scientific Sessions of the American Diabetes Association; June 9-13, 2006; Washington, DC. Abstract 1994-PO.
52. Peters Harmel AL, Kendall DM, Buse JB, et al. Impact of adjunctive thiazolidinedione therapy on blood lipid levels and glycemic control in patients with type 2 diabetes. Curr Med Res Opin. 2004;20:215-223.
53. Qayyum R, Adomaytyte J. A meta-analysis of the effects of thiazolidinediones on blood pressure. J Clin Hypertens. 2006;8:19-28.
54. Reaven G. Role of insulin resistance in human disease. Diabetes. 1988;37:1595-1607.
55. Rosak C. The pathophysiologic basis of efficacy and clinical experience with the new oral antidiabetic agents. J Diabetes Complications. 2002;16:123-132.
56. Schernthaner G, Matthews DR, Charbonnel B, et al. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. J Clin Endocrinol Metab. 2004;89:6068-6076.
57. Seufert J. A fixed-dose combination of pioglitazone and metformin: A promising alternative in metabolic control. Curr Med Res Opin. 2006;22(Suppl. 2):s39-s48.
58. Sharma PK, Bhansali A, Sialy R, et al. Effects of pioglitazone and metformin on plasma adiponectin in newly detected type 2 diabetes mellitus. Clin Endocrinol. 2006;65:722-728.
59. Singh S, Loke YK, Furberg CD. Long term risk of cardiovascular events with rosiglitazone. A meta-analysis. JAMA. 2007;298:1189-1195.
60. Spanheimer R, Perez A, Kupfer S, et al. The effects of pioglitazone vs glyburide on glycemic control in patients with type 2 diabetes in a 3-year randomized double-blind trial. Presented at: 66th Scientific Sessions of the American Diabetes Association; June 9-13, 2006; Washington, DC. Abstract 320-OR
61. Standl E, Fuchtenbusch M. The role of oral antidiabetic agents: Why and when to use an early phase insulin secretion agent in type 2 diabetes mellitus. Diabetologia. 2003;46(Suppl. 1):M30-M36.
62. Takiya L, Chawla S. Therapeutic options for the management of type 2 diabetes mellitus. Am J Manag Care. 2002;8:1009-1023.
63. Umpierrez G, Issa M, Vlajnic A. Glimepiride versus pioglitazone combination therapy in subjects with type diabetes inadequately controlled on metformin monotherapy: Results of a randomized clinical trial. Curr Med Res Opin. 2006;22:751-759.
64. UKPDS (UK Prospective Diabetes Group). Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854-865.
65. van Wijk JP, de Koning EJ, Martens EP, et al. Thiazolidinedones and blood lipids in type 2 diabetes. Arterioscler Thromb Vasc Biol. 2003;23:1744-1749.
66. White JR, Davis SN, Cooppan R, et al. Clarifying the role of insulin in type 2 diabetes management. Clin Diabetes. 2003;21:14-21.